House Republicans Seek Top Down Change To FDA’s Warning-Letter Appeals
This article was originally published in The Tan Sheet
Executive Summary
FDA leadership needs to review the agency's enforcement dispute resolution process, according to ranking Republicans on the House Energy and Commerce Committee
You may also be interested in...
House Republicans Challenge FDA On Warning Letter Appeals Process
Senior Republicans on the House Energy & Commerce Committee are challenging FDA on the fairness of its warning letter appeals process, questioning whether the agency "really provides a good-faith option of appeal.
Pharmachem Gains Phase 2 Claims Agreement, Plus Patent For New Product
Pharmachem Laboratories' experience with claims for its Phase 2 starch-neutralizer branded ingredient may provide an example for firms seeking to validate claims with the FDA, the firm says
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.